Company intelligence / Profile preview

WomenX Biotech Limited

Hong Kong, N/A, Hong Kong SARwomenx.net ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

WomenX Biotech has developed a market-first period pad ("PadX") that detects HPV from menstrual blood with 99.2% accuracy in initial tests on 119 participants. The company is running clinical trials to validate urine and menstrual blood biomarkers for cervical cancer screening. Their technology aims to provide accessible, non-invasive alternatives to traditional cervical screening methods[5][7].

Therapeutic areas: OncologyWomen's HealthInfectious Diseases
Modalities: Biomarker discovery (proteins, DNA)Diagnostic devices (e.g., period pad for HPV detection)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

PadX

Commercial

Indications: HPV detection

Partnerships

Pangenia Group – private medical testing laboratory partner for processing PadX samples[5]

Beyond the preview

Go deeper on WomenX Biotech Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WomenX Biotech Limited.

Explore the full profile